Posted on · The new shots from Moderna and Pfizer-BioNTech target both the original strain of the coronavirus and the omicron BA.4/BA.5 subvariants that most people are catching now.
Posted on · In a highly anticipated decision, the Food and Drug Administration authorized Pfizer's Paxlovid as the first antiviral pill to treat COVID-19 at home.
Posted on · The Food and Drug Administration also gave an OK to boosters that differ from the vaccine originally used to immunize people against COVID-19. A mix-and-match approach could ease the booster rollout.
Posted on · A third shot of the vaccine can be given at least six months after the two-dose regimen, according to the authorization. A booster rollout could begin this week.
Posted on · Advisers to the Food and Drug Administration voted against approval of a booster of the Pfizer-BioNTech COVID-19 vaccine for people 16 years and older. They later supported boosters for older people.
Posted on · The approval replaces the emergency use authorizations granted last December and could make it easier for employers, the military and universities to mandate vaccination.
Posted on · The Food and Drug Administration typically follows the advice of its expert advisers. A quick agency decision on the Johnson & Johnson vaccine is expected given the state of the pandemic.
Posted on · In a 17-4 vote, an expert committee concluded that the scientific evidence supports the authorization of the COVID-19 vaccine from Pfizer and BioNTech for emergency use during the pandemic.
Posted on · The Food and Drug Administration finds "no specific safety concerns" that would stand in the way of authorization of the vaccine for emergency use. Effectiveness is 95% after two doses.